Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | HPGD | P15428 | 1/20 | 0.81 |
| ▸ | HTT | P42858 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | KDR | P35968 | 11/20 | 0.72 |
| ▸ | FLT1 | P17948 | 2/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | CSF1R | P07333 | 1/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.66 |
| ▸ | KIT | P10721 | 1/20 | 0.66 |
| ▸ | FLT4 | P35916 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | PPIA | P62937 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4405252 | 0.99 | RXFP1 (0.80) | RXFP1MEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL427615 | 0.93 | KDR (0.84) | RXFP1MEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL3106390 | 0.92 | KDR (0.70) | RXFP1MEN1MAPTKMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL447740 | 0.92 | KDR (0.83) | RXFP1MEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL3122487 | 0.91 | RXFP1 (0.71) | RXFP1MEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL3110637 | 0.89 | KDR (0.66) | RXFP1MEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL15528901 | 0.88 | KDR (0.87) | RXFP1MEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL3110867 | 0.87 | RXFP1 (0.66) | RXFP1MEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL3108780 | 0.87 | KDR (0.66) | RXFP1MEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL427746 | 0.86 | RXFP1 (0.65) | RXFP1MEN1MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168948-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-03-31 | — | — | EP | claimed |
| EP-1259487-B1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | claimed |
| US-6624174-B2 | Especially for treating a neoplastic disease, retinopathy or age-related macular degeneration | NOVARTIS AG (CH) | 2003-09-23 | — | — | US | claimed |
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2003-02-13 | — | — | US | claimed |
| EP-2168948-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-1259487-B1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-6624174-B2 | Especially for treating a neoplastic disease, retinopathy or age-related macular degeneration | NOVARTIS AG (CH) | 2003-09-23 | — | — | US | disclosed |
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2003-02-13 | — | — | US | disclosed |
| EP-1259487-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001055114-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | KDR, ERBB2, FLT1 | RXFP1 957/4885MEN1 4248/4885MAPT 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.